Your browser is no longer supported. Please, upgrade your browser.
Settings
TGTX TG Therapeutics, Inc. daily Stock Chart
TGTX [NASD]
TG Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.98 Insider Own1.40% Shs Outstand76.56M Perf Week-9.67%
Market Cap930.20M Forward P/E- EPS next Y-1.89 Insider Trans-6.32% Shs Float63.88M Perf Month-16.78%
Income-132.30M PEG- EPS next Q-0.53 Inst Own56.40% Short Float18.64% Perf Quarter-15.63%
Sales0.20M P/S4651.02 EPS this Y-19.60% Inst Trans0.32% Short Ratio11.74 Perf Half Y29.95%
Book/sh1.21 P/B10.04 EPS next Y8.30% ROA-125.60% Target Price29.67 Perf Year3.85%
Cash/sh1.43 P/C8.53 EPS next 5Y- ROE-170.80% 52W Range7.25 - 17.35 Perf YTD48.17%
Dividend- P/FCF- EPS past 5Y-6.70% ROI- 52W High-29.97% Beta1.23
Dividend %- Quick Ratio3.50 Sales past 5Y51.60% Gross Margin- 52W Low67.59% ATR0.69
Employees76 Current Ratio3.50 Sales Q/Q0.00% Oper. Margin- RSI (14)40.03 Volatility7.98% 5.40%
OptionableYes Debt/Eq0.00 EPS Q/Q-12.70% Profit Margin- Rel Volume0.91 Prev Close12.20
ShortableYes LT Debt/Eq0.00 EarningsAug 07 BMO Payout- Avg Volume1.01M Price12.15
Recom1.50 SMA20-7.45% SMA50-10.09% SMA2002.62% Volume919,956 Change-0.41%
Mar-09-18Reiterated B. Riley FBR, Inc. Buy $21.50 → $27
Dec-01-17Resumed B. Riley FBR, Inc. Buy $21.50
Nov-14-17Resumed H.C. Wainwright Buy $33
Apr-25-17Initiated Jefferies Buy
Mar-06-17Reiterated FBR & Co. Outperform $24 → $26
Oct-06-16Resumed Brean Capital Buy $28
May-27-16Initiated SunTrust Buy $18
Dec-01-15Initiated FBR Capital Outperform $29
Sep-09-15Initiated Raymond James Strong Buy
Aug-12-15Resumed H.C. Wainwright Buy $22
Jun-19-15Reiterated Brean Capital Buy $22 → $28
Dec-11-14Reiterated ROTH Capital Buy $25 → $33
Dec-10-14Reiterated ROTH Capital Buy $25 → $33
Oct-27-14Initiated H.C. Wainwright Buy $17
Sep-25-14Reiterated Brean Capital Buy $19 → $22
Jul-22-14Reiterated Brean Capital Buy $13 → $19
Jul-02-14Reiterated MLV & Co Buy $10 → $16
Apr-04-14Initiated Brean Capital Buy $13
Mar-07-14Reiterated MLV & Co Buy $9 → $11
Nov-25-13Reiterated Ladenburg Thalmann Buy $8 → $12
Jul-10-18 08:40AM  Implied Volatility Surging for TG Therapeutics (TGTX) Stock Options Zacks
07:35AM  Complimentary Technical Snapshots on Trevena and Three More Biotech Stocks ACCESSWIRE
Jun-20-18 07:30AM  TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody GlobeNewswire
Jun-18-18 12:00PM  TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology GlobeNewswire
07:30AM  TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA) GlobeNewswire
Jun-15-18 09:17AM  TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European Hematology Association GlobeNewswire
08:13AM  TG Therapeutics, Inc. Announces Oral Presentation of Umbralisib plus Ruxolitinib in Patients with Myelofibrosis at the 23rd Congress of the European Hematology Association GlobeNewswire
Jun-12-18 04:29PM  This Biotech Investors Picks Returned 31% in Q1; Here Are Its New Bets Insider Monkey
Jun-08-18 07:00AM  TG Therapeutics and Three Additional Stocks Under Scanner in the Biotech Space ACCESSWIRE
06:04AM  3 Cancer Stocks That Could Soar in the Second Half of 2018 Motley Fool
Jun-05-18 07:30AM  TG Therapeutics, Inc. to Present at the Jefferies 2018 Global Healthcare Conference GlobeNewswire
Jun-04-18 04:06PM  ASCO 2018 Sends TG Therapeutics Stock Soaring 10% Today Motley Fool +10.78%
09:00AM  TG Therapeutics, Inc. Announces Umbralisib Clinical Data Presentation at the 54th Annual Meeting of the American Society of Clinical Oncology GlobeNewswire
07:30AM  TG Therapeutics, Inc. Appoints Adam Waldman as Chief Commercial Officer GlobeNewswire
Jun-01-18 07:30AM  TG Therapeutics, Inc. Recaps Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association GlobeNewswire
May-17-18 09:10AM  TG Therapeutics, Inc. Announces Upcoming Data Presentations at the 54th Annual Meeting of the American Society of Clinical Oncology and the 23rd Congress of the European Hematology Association GlobeNewswire
May-14-18 07:51PM  Edited Transcript of TGTX earnings conference call or presentation 8-May-18 12:30pm GMT Thomson Reuters StreetEvents +5.34%
May-08-18 07:53AM  TG Therapeutics: 1Q Earnings Snapshot Associated Press -6.51%
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports First Quarter 2018 Financial Results GlobeNewswire
May-04-18 07:30AM  TG Therapeutics, Inc. to Host Conference Call on First Quarter 2018 Financial Results and Business Update GlobeNewswire
Apr-30-18 08:20AM  Recent Analysis Shows FTD Companies, TG Therapeutics, National HealthCare, Lennox International, PRA Group, and Unit Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Apr-24-18 08:06AM  TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the American Academy of Neurology 70th Annual Meeting GlobeNewswire
Apr-20-18 08:03AM  3 Biotech Stocks With Major Catalysts Incoming Motley Fool
Apr-18-18 09:00AM  TG Therapeutics, Inc. Announces Preclinical Data Presentation on the Companys BET Inhibitor, TG-1601, at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Apr-16-18 07:00AM  Stemline Therapeutics Expands Board of Directors; Further Enhances Commercial Expertise with Appointment of Darren Cline GlobeNewswire
Mar-26-18 07:30AM  TG Therapeutics, Inc. to Present at the Needham 17th Annual Healthcare Conference GlobeNewswire
Mar-15-18 07:30AM  TG Therapeutics, Inc. Announces Preclinical Data Presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-09-18 02:21PM  Edited Transcript of TGTX earnings conference call or presentation 8-Mar-18 1:30pm GMT Thomson Reuters StreetEvents
Mar-08-18 09:36AM  TG Therapeutics reports 4Q loss Associated Press +7.87%
07:30AM  TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2017 Financial Results and Business Update GlobeNewswire
Mar-06-18 07:30AM  TG Therapeutics, Inc. to Host Conference Call on Fourth Quarter and Year-End 2017 Financial Results and Business Update GlobeNewswire
Mar-02-18 07:30AM  TG Therapeutics, Inc. to Present at Upcoming Investor Conferences GlobeNewswire
Feb-27-18 07:07PM  Cramer's lightning round: Wall Street youngsters are weig... CNBC Videos
06:50PM  Cramer's lightning round: Wall Street youngsters are weighing on oil stocks CNBC
07:45AM  New Research Coverage Highlights Atkore International Group, Virtusa, Aceto, Cullen/Frost Bankers, TG Therapeutics, and Boingo Wireless Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Feb-21-18 05:18PM  Why TG Therapeutics Stock Jumped 10% Today Motley Fool +9.92%
07:30AM  TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1 First-in-Human Trial of Umbralisib in The Lancet Oncology GlobeNewswire
Feb-07-18 11:23AM  Harry Boxers three stocks breaking out on earnings news MarketWatch
Feb-05-18 08:30AM  Todays Research Reports on Trending Tickers: Array BioPharma and TG Therapeutics ACCESSWIRE
Feb-04-18 11:02AM  Growth Stocks Investors Love Simply Wall St.
08:01AM  3 Boom-or-Bust Biotech Stocks to Buy in 2018 Motley Fool
Feb-02-18 06:30AM  TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab (TG-1101) in Patients with Multiple Sclerosis at the Third Annual ACTRIMS Forum 2018 GlobeNewswire
Jan-24-18 07:30AM  TG Therapeutics, Inc. Announces Data Presentation at the Upcoming Third Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2018 GlobeNewswire
Jan-11-18 05:02PM  Why TG Therapeutics Rallied 15.7% Today Motley Fool +15.76%
Jan-08-18 07:30AM  TG Therapeutics, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference GlobeNewswire
07:30AM  TG Therapeutics and Jiangsu Hengrui Medicine Announce Global License Agreement for Development and Commercialization of Novel BTK Inhibitor Program for the Treatment of Hematologic Malignancies GlobeNewswire
Jan-03-18 11:02AM  January Top Growth Stocks Simply Wall St. +5.71%
Dec-20-17 07:35AM  Market Trends Toward New Normal in TG Therapeutics, Boingo Wireless, Dave & Buster's Entertainment, Flagstar, Superior Industries International, and Benchmark Electronics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:22AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : December 20, 2017 Capital Cube
Dec-11-17 02:12PM  ETFs with exposure to TG Therapeutics, Inc. : December 11, 2017 Capital Cube
10:38AM  TG Therapeutics Inc (TGTX): Does -30.2% EPS Decline Lately Make It An Underperformer? Simply Wall St.
07:00AM  TG Therapeutics, Inc. Announces Preclinical & Clinical Data Presentations at the 59th American Society of Hematology Annual Meeting GlobeNewswire
Dec-08-17 08:06AM  TG Therapeutics, Inc. Recaps Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting GlobeNewswire
Nov-30-17 02:28PM  ETFs with exposure to TG Therapeutics, Inc. : November 30, 2017 Capital Cube
Nov-29-17 08:42AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017 Capital Cube
Nov-27-17 07:30AM  TG Therapeutics Announces Initiation of National Cancer Institute/SWOG-Sponsored Randomized Phase II Trial in Follicular Lymphoma GlobeNewswire
Nov-22-17 08:20AM  Todays Research Reports on Trending Tickers: MannKind Corporation and TG Therapeutics ACCESSWIRE
Nov-14-17 12:29PM  Edited Transcript of TGTX earnings conference call or presentation 8-Nov-17 1:30pm GMT Thomson Reuters StreetEvents
Nov-08-17 08:03AM  TG Therapeutics reports 3Q loss Associated Press
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Nov-06-17 07:30AM  TG Therapeutics, Inc. to Host Conference Call on Third Quarter 2017 Financial Results and Business Update GlobeNewswire -5.42%
Nov-01-17 09:30AM  TG Therapeutics, Inc. Announces Data Presentations at the Upcoming 59th American Society of Hematology Annual Meeting GlobeNewswire
Oct-31-17 07:30AM  TG Therapeutics, Inc. to Host Post ECTRIMS-ACTRIMS Conference Call to Review Data Presented on TG-1101 (ublituximab) in Multiple Sclerosis GlobeNewswire
Oct-27-17 07:30AM  TG Therapeutics, Inc. Announces Additional Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Oct-26-17 07:30AM  TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Oct-17-17 08:10AM  Today's Research Reports on Stocks to Watch: Aratana Therapeutics and TG Therapeutics ACCESSWIRE -9.16%
Oct-16-17 02:20PM  Why TG Therapeutics Is Tumbling 15% Today Motley Fool -15.68%
07:30AM  TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
07:30AM  TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial GlobeNewswire
07:30AM  TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire
Oct-12-17 08:24AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : October 12, 2017 Capital Cube
Oct-05-17 07:30AM  TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development GlobeNewswire
Sep-29-17 08:47AM  Why You Need To Look At This Factor Before Buying TG Therapeutics Inc (TGTX) Simply Wall St.
07:30AM  TG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS) GlobeNewswire
Sep-28-17 10:30AM  TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : September 28, 2017 Capital Cube
Sep-27-17 08:17AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : September 27, 2017 Capital Cube
Sep-21-17 07:30AM  TG Therapeutics, Inc. to Present at Upcoming Investor Conferences GlobeNewswire
Sep-15-17 07:30AM  TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment GlobeNewswire
Sep-13-17 11:01AM  Should You Buy TG Therapeutics Inc (TGTX) Now? Simply Wall St.
Sep-05-17 07:30AM  TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial GlobeNewswire
Sep-01-17 07:30AM  TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS ACTRIMS Meeting GlobeNewswire
Aug-31-17 09:31PM  ETFs with exposure to TG Therapeutics, Inc. : September 1, 2017 Capital Cube
Aug-24-17 10:13AM  TG Therapeutics, Inc. :TGTX-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-14-17 08:28AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : August 14, 2017 Capital Cube
Aug-13-17 02:31AM  Edited Transcript of TGTX earnings conference call or presentation 9-Aug-17 12:30pm GMT Thomson Reuters StreetEvents
Aug-10-17 07:30AM  TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial GlobeNewswire
Aug-09-17 01:01PM  TG Therapeutics reports 2Q loss Associated Press
07:30AM  TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results GlobeNewswire
05:50AM  Investor Network: TG Therapeutics, Inc. to Host Earnings Call ACCESSWIRE
Aug-07-17 05:04PM  What's Behind TG Therapeutics Inc.'s 14.4% Rally in July? Motley Fool
07:30AM  TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update GlobeNewswire
Aug-03-17 11:37PM  TG Therapeutics, Inc. Value Analysis (NASDAQ:TGTX) : August 4, 2017 Capital Cube -5.88%
Aug-02-17 09:13AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : August 2, 2017 Capital Cube
Aug-01-17 07:30AM  TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS) GlobeNewswire
Jul-25-17 01:35PM  ETFs with exposure to TG Therapeutics, Inc. : July 25, 2017 Capital Cube -5.81%
Jul-21-17 08:37AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : TGTX-US : July 21, 2017 Capital Cube
Jul-14-17 05:08PM  ETFs with exposure to TG Therapeutics, Inc. : July 14, 2017 Capital Cube
Jun-28-17 09:02AM  TG Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : TGTX-US : June 28, 2017 Capital Cube
Jun-26-17 07:30AM  TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress GlobeNewswire
07:00AM  TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology GlobeNewswire
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Power Sean ACFO, Secretary and TreasurerJul 03Sale13.1935,000461,650438,267Jul 05 05:00 PM
Power Sean ACFO, Secretary and TreasurerJul 02Sale13.2612,191161,653473,267Jul 05 05:00 PM
KENNEDY WILLIAM JAMESDirectorJun 14Sale13.4525,071337,20560,330Jun 18 04:30 PM
Power Sean ACFO, Secretary and TreasurerJan 02Sale8.5032,006272,051485,458Jan 03 05:25 PM